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Abstract
Objective—Non-adherence is currently an under-recognized and potentially modifiable obstacle 
to care in juvenile idiopathic arthritis (JIA). The purpose of this study was to design and 
implement a standardized approach to identifying adherence barriers for youth with JIA across 
seven pediatric rheumatology clinics via the Pediatric Rheumatology Care and Outcomes 
Improvement Network (PR-COIN) and assess the frequency of adherence barriers in patients and 
their caregivers across treatment modalities.
Methods—An iterative process utilizing coproduction amongst parents and providers of patients 
with JIA was used to design the Barriers Assessment Tool (BAT) to screen for adherence barriers 
across four treatment modalities (i.e., oral medications, injectable medications, infusions, and 
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physical/occupational therapy). This tool was implemented in seven rheumatology clinics across 
the United States and patient responses were collected for analysis.
Results—Data were collected from n=578 parents and n=99 patients (n=44 parent-child dyads). 
Seventy-seven percent (n=444) of caregivers and 70% (n=69) of patients reported at least one 
adherence barrier across all treatment components. The most commonly reported adherence 
barriers included worry about future consequences of therapy, pain, forgetting, side-effects, and 
embarrassment related to the therapy. There was no significant difference between endorsement of 
barriers between parents and adolescents.
Conclusion—Implementing a standardized tool assessing adherence barriers in the JIA 
population across multiple clinical settings is feasible. Systematic screening sheds light on the 
factors that make adherence difficult in JIA and identifies targets for future adherence 
interventions in clinical practice.
Key Indexing Terms
Juvenile Arthritis; Patient Compliance; Quality Improvement
Introduction
Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic condition 
composed of seven unique phenotypic subtypes with varied clinical course severities and 
spectrums of morbidity.1 The treatment landscape in JIA has rapidly evolved since the 
advent of biologic medications. Clinical trials focused on safety and efficacy have proven 
favorable prognostic outcomes when controlled dosing of medications are administered.2–5 
However, despite treatment advances, only 16-64% of the disease course is spent in a 
clinically inactive state when assessed across all JIA subtypes.6 Even in patients who attain 
inactive disease status, the risk of flare within one year is 40%.7 Moreover, long-term 
outcomes into adulthood reveal sustained limitations in functioning resulting in negative 
impacts on health-related quality of life.8,9
Non-adherence represents a modifiable factor that could significantly impact outcomes, 
including morbidity, mortality, costs, healthcare decision-making, and health-related quality 
of life.10 Adherence is defined as the extent to which a person’s behavior corresponds with 
provider health recommendations.11 While adherence rates vary among general pediatric 
populations, average adherence is 50%.12 Studies of adherence in JIA have been limited, 
with most focusing on self- and parent-reported adherence, which tend to be inflated relative 
to more objective measures (e.g., electronic monitoring). One study assessing adherence to 
non-steroidal anti-inflammatory medications in newly diagnosed JIA patients classified 52% 
of patients as adherent.13 Interestingly, even more sophisticated therapies, such as biologic 
medications and disease modifying anti-rheumatic drugs (DMARDs), have suboptimal rates 
of adherence, with a mean medication refill possession ratio of 46.9% and 65.7% for 
subcutaneous methotrexate and injectable tumor necrosis factor- alpha inhibitors, 
respectively.14 Factors predicting non-adherence in JIA include delayed time to therapeutic 
efficacy, fear of adverse effects, chronicity of disease and complex and costly regimens.15–17 
Conversely, factors associated with higher perceived adherence included perceived 
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helpfulness of treatment, lower disease severity and younger age of the child.18 Despite what 
is known about non-adherence in JIA, there remains critical gaps in translating research 
findings into clinical practice. In fact, pediatric rheumatologists are unlikely to address 
adherence barriers in routine practice, especially when compared to treatment efficacy/
performance.16
Identification of JIA-specific barriers is an important first step in adherence promotion, 
especially in clinical practice. The Health Belief Model postulates the importance of 
perceptions of barriers as a factor contributing to non-adherence, and served as a theoretical 
framework that prompted the systematic screening of barriers in our current study.19 
Research has demonstrated that as the number of patient-reported barriers increases, 
adherence to treatment decreases.20 One study noted the impact of cumulative barriers, 
finding that each additional barrier to adherence increased the likelihood of non-adherence 
by approximately 30%.21 Furthermore, we know from pediatric and adult literature that 
repeated measures of barriers to adherence are necessary as individual barriers are variable 
as the patient ages and disease status evolves.22,23 Barriers identified in the larger pediatric 
literature (e.g., asthma, cystic fibrosis, solid organ transplant, inflammatory bowel disease) 
include forgetting, medication side effects or palatability, child oppositional behaviors and 
interference in daily life.24–26 Understanding and identifying individual barriers will allow 
providers to target specific areas for intervention to promote adherence and self-
management. Meta-analyses have demonstrated that multi-component interventions to 
address adherence can improve health outcomes and health care utilization.27,28 
Unfortunately, few studies have identified barriers to target for multi-modal adherence 
interventions in JIA, especially since the advent of biologic medications.
The current study used quality improvement methodology to design and test a barriers 
assessment tool specific for the JIA population, as well as to identify patient and parent-
reported adherence barriers across several JIA treatments. The collaboration of a multi-
center team of pediatric rheumatology providers, psychologists, and parent representatives 
was organized by the Pediatric Rheumatology Care and Outcomes Improvement Network 
(PR-COIN). This international collaborative learning network is centered on the cooperative 
development and implementation of management strategies to improve the outcomes and 
quality care for patients with JIA. PR-COIN provided formal education and hands-on 
training in the field of self-management across seven of 18 PR-COIN member sites prior to 
the development of the adherence barriers screening tool. Our hypothesis was that this 
barrier assessment tool would comprehensively identify adherence barriers that would not 
have otherwise been discussed during a routine clinic visit. The second goal was to facilitate 
the systematic distribution of the barriers assessment across all seven sites. Finally, our team 
aimed to assess for concordance of adherence barriers across caregiver and patient dyad 
respondents. Consistent with prior literature, it was hypothesized that forgetting, side effects, 
and interference with daily life would be the most highly endorsed barriers across various 
treatment components (e.g., oral medications, injections, infusions, and physical and 
occupational therapy).
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Patients and Methods
Design of the Barriers Assessment Tool
Seven centers (Children’s Mercy Kansas City, Cincinnati Children’s Hospital Medical 
Center, Cohen Children’s Medical Center, Levine Children’s Hospital, Stanford Children’s 
Hospital, Nationwide Children’s Hospital, and Penn State Children’s Hospital) were 
involved in the design and implementation of the Barriers Assessment Tool through PR-
COIN. A multidisciplinary co-production model was used, including pediatric 
rheumatologists, nurse practitioners, psychologists, and parents of children with JIA. Co-
production is a collaborative approach in which all stakeholders including patients, 
caregivers and providers are involved in the project initiative from conceptualization to 
implementation. While this exact self-report measure was newly developed for this project, 
design of the Barriers Assessment Tool was based on prior work in other pediatric 
subspecialties.24, 26,29,30 Validation studies have demonstrated that adherence barriers are 
strongly correlated with both adherence and health outcomes (e.g., organ rejection, seizures).
26,29,30
 An iterative process via monthly teleconferencing was utilized to create, modify, and 
individually tailor the Barriers Assessment Tool for patients with JIA. Engagement of the 
families in the feedback and design process was valuable in tailoring a tool that would be 
specific to this unique population. Important re-design feedback included reconfiguring the 
tool to ease usability, as well as altering the checklist to include JIA-specific barriers across 
various treatment components. Streamlined design was of paramount importance to the co-
production team with emphasis on keeping the tool limited to one page in length. Care was 
taken to limit word density and check-boxes were utilized to further simplify the tool. An 
important goal of the team was to avoid contributing to “form fatigue” and provide the most 
information with the least amount of patient or caregiver effort. The final Barriers 
Assessment Tool is composed of a 17-item checklist spanning four treatment modalities- 
oral medications, injections, infusions and physical/occupational therapy. Barrier themes 
include regimen characteristics (i.e. palatability and complexity), logistical impedances, 
patient oppositional behavior, social difficulties and efficacy concerns. Although the general 
layout remained consistent between the tools designed for other patient populations (e.g., 
kidney transplantation and epilepsy), specific barriers and treatment regimens were added. 
Examples of JIA specific regimens included the addition of injections, infusions and 
physical/occupational therapy. Worry for future side effects and concern for future child-
bearing were barriers that patients and caregivers independently identified in JIA, in addition 
to more universal barriers (i.e. forgetting or poor taste). Two versions of the assessment were 
designed, one for caregivers and one for children 10 years old or older. Age 10 was chosen 
based on developmental ability to independently complete the forms.
Implementation of the Barriers Assessment Tool
The Barriers Assessment Tool was successfully administered to patients and/or parents at the 
seven PR-COIN centers. Cincinnati Children’s Hospital Medical Center (CCHMC) served 
as the Central IRB and the coordinating center for the study. The study protocol was first 
approved through the Central IRB (IRB #2010-2811). Additionally, local IRB approval of 
the protocol was obtained for the following sites: Cohen Children’s Medical Center, Levine 
Children’s Hospital, Stanford Children’s Hospital, Nationwide Children’s Hospital, and 
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Penn State Children’s Hospital. All scheduled patients with JIA during the seven-month 
testing period (March – September 2016) were eligible to participate. Participants 
represented all JIA subtypes and ages and had to be currently receiving one or more of the 
treatment modalities (oral medications, injections, infusions or physical/occupational 
therapy) at the time of participation. Informed consent was not required by respective 
institutions as this was undertaken as a quality improvement initiative. All parents were 
asked to complete a Barriers Assessment Tool, and children 10 years old or older were given 
their own form to capture parent-patient dyad responses. Improvement science principles 
and tools were applied across sites to facilitate the work, including development of a Key 
Driver Diagram, process flow maps, iterative Plan-Do-Study-Act (PDSA) cycles based upon 
key drivers to design reliable implementation processes. The Model for Improvement was 
utilized as the framework to guide the process and improve integration into care delivery.31 
The primary process measure was the percent of indicated Barriers Assessment Tools that 
were successfully collected. As this was a quality improvement initiative, patient identifiers 
were not linked to completed questionnaires and thus demographics (i.e. JIA subtype, age, 
race, disease severity) were unable to be obtained in the current project.
Teleconferencing was used to share data and the experience of implementation in varying 
busy clinic flow scenarios. The group problem-solved ways to improve execution. Site-
specific processes of implementation varied based on local staffing resources; however, 
broad solutions included clearly defining staff responsibilities and linking distribution of the 
assessment to an already established process, such as morning clinic set-up. Although there 
was no measurement of the visit time burden of introducing this tool, there was provider 
feedback that the tool allowed a swift inventory of patient or parent concerns that led to 
productive conversations. While repeat measurements from the same patient were possible, 
this was unlikely given the short testing time-frame in relation to typical JIA follow up 
appointment timing.
Statistical Analysis of Barriers Assessment Tool Responses
Descriptive statistics, including means, standard deviations, and frequencies, were used to 
examine barriers. Each barrier was scored as either ‘0’ (not endorsed) or ‘1’ (endorsed). We 
used paired-sample t tests to assess frequency differences in barriers across treatment 
modalities. McNemar tests were conducted to examine differences in the endorsement and 
concordance between parent-child dyads. Analyses were performed with the Statistical 
Package for Social Sciences (SPSS), Version 24.32
Results
Endorsement and Types of Barriers
A total of 677 barrier assessments were collected out of 1148 eligible patients over the study 
testing period (59% completion rate). The collected assessments included 578 parent and 99 
patient responses, with 44 identified parent-child dyads across the seven participating PR-
COIN sites. Of those respondents, 76.8% (n=444) parents and 69.7% (n=69) patients 
reported at least one adherence barrier across all treatment components. The most commonly 
endorsed barriers among patients and parents stratified by treatment modality are presented 
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in Figure 1 and 2. Notably, worry about future treatment consequences, pain, forgetting, side 
effects, and embarrassment were the top barriers among both parents and patients.
Barriers to oral medications were endorsed in 44.6% (n=258) of parents and 47.5% (n=47) 
of patients. Top oral medication barriers included worry about future consequences, 
forgetting and poor taste. Barriers of any type for injectable medications were endorsed in 
52.5% (n=304) of parents and 40.4% (n=40) of patients. Infusion barriers were endorsed in 
12.7% (n=73) and 9% (n=9) of parents and patients respectively. The most highly endorsed 
barriers for both injectable and infusion medication were worry, pain and side effects. 
Barriers to physical and occupational therapy were noted in 13% (n=75) of parents and 14% 
(n=14) of patients. The top reported barriers for physical and occupational therapy were 
forgetting, pain and believing the therapy is unnecessary.
Most parents (M=2.83± 3.20) and patients (M=2.80± 2.90) endorsed less than three barriers. 
The number of injection barriers endorsed (M=1.37+1.73) was significantly higher 
compared to oral medications (M=0.95+1.43; p <0.01) in parents. No significant differences 
were found among treatment modalities for the frequency of patient-reported barriers.
Caregiver-Patient Convergence on Barriers to Adherence
McNemar tests were performed to examine differences in the endorsement of barriers 
between the forty-four parent-patient dyads. Separate tests evaluated for agreement for each 
barrier per treatment modality. Both parents and patients tended to agree on barriers 
endorsed within categories of therapy. No significant differences were found between the 
barriers endorsed for oral medications (16% vs. 19%), injections (24% vs. 22%), infusions 
(3% vs. 4%), or physical/occupational therapy (10% vs. 11%) between the dyads.
Discussion
The current study sought to systematically assess parent and patient treatment barriers in JIA 
across individual treatment modalities through the leverage of a learning network. The 
majority of participants expressed at least one barrier to a treatment modality, which 
highlights the importance of such a screening tool to encourage discussion of treatment 
adherence in clinical care. This is a new addition to our current care framework which does 
not currently emphasize screening for adherence barriers as compared to addressing 
therapeutic performance.16
Common barriers endorsed included largely actionable concerns, such as poor taste, 
forgetting, pain and difficulty managing side effects. Evidence-based treatments to address 
several of these barriers have been developed and have been found to be efficacious.33–35 
The provision of intervention tools to address these common barriers with patients and 
caregivers in clinical practice is critical to addressing the needs of the patient and improving 
adherence. A pilot adherence initiative in kidney transplantation has found that 
systematically identifying and addressing adherence barriers to immunosuppressant therapy 
improved population-based outcomes (i.e., late organ rejection).36
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The most commonly endorsed barrier across all treatment modalities was worry about future 
consequences of receiving the therapy. This is a JIA-specific barrier that has not been 
identified in other pediatric populations but is quite salient with the use of biologics, which 
have relatively short term data regarding adverse effect risks in children.37,38 Familial 
assurance regarding appropriate therapeutic decisions balanced against the risk of long term 
disease-related damage is largely up to individual providers, making this a variable 
experience overall.39 One qualitative study of pediatric patients prescribed tumor necrosis 
factor- alpha inhibitor biologics highlighted that the current education and decision making 
process in rheumatology and gastroenterology clinics ultimately led to long-term worry and 
concern surrounding therapy.40 Families acquire information about prospective therapies 
from multiple sources, including medical care providers, the internet and social contacts, 
making clear access to unbiased and timely information more important than ever.41 Shared-
decision making techniques could be beneficial in reducing concern and uncertainty and 
ultimately improve adherence to treatment recommendations. Systematically implementing 
patient-centered tools or decision aides for treatment education is one way to navigate 
varying patient and provider approaches.42
Interestingly, injectable medications, which are most often given in the home by either the 
patient or parent, had the highest endorsement of barriers, even when compared to hospital 
infusion therapy. These findings suggest that home-based injections may create a more 
burdensome experience for families when compared to hospital infusions. This may be 
counterintuitive because hospital infusions require additional transportation and time 
requirement for families. While common injection barriers include pain, discomfort and 
refusal, worry about future consequences was also markedly higher in families receiving 
injectable medications compared to infusion therapy. It is possible that the actual act of 
caregivers or patients administering injections, rather than hospital staff, amplifies these 
concerns despite the added convenience that an in-home injection could provide. While this 
is the first time a comparison of perceived worry between injectable and infusion therapy has 
been attempted, the impact of the general care of patients with JIA on psychological health 
and quality of life for caregivers has been established in our population.43 This finding could 
suggest that increased training initiatives and education surrounding injection administration 
may be helpful to prevent such barriers.
Although no differences were found between parents and patients in either number or type 
of barriers expressed, we still believe it is important to gather both perspectives. It has been 
previously described that adolescents with JIA and their parents exhibit meaningful 
differences in their responses regarding treatment helpfulness and adherence.44,45 Formal 
screening and discussion of potential discrepancies may help to facilitate communication 
between provider, patient and caregiver to better understand differing goals of therapy. 
While there is variability in age at which adolescents transition to assuming more 
responsibility of their medication and exercise regimens, this is an important time of skill 
building for fostering interest in their own care. In a study involving initiation of biologic 
therapy in JIA and Crohn’s Disease, most adolescents valued the involvement of their 
physician or parent in treatment decisions, but given the chance would have preferred more 
active participation and dedicated education.46
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There are some notable limitations to this study that deserve consideration. While our 
barriers assessment tool was newly designed for this project without formal validation, the 
themes depicted in our tool have been systematically and rigorously validated in other 
pediatric chronic illness populations.26,29,30 A correlation of our tool with quantitative 
measurement of adherence would have been optimal to translate endorsed barriers with 
actual behavior. Self- or parental-reported adherence would have also added to the richness 
of this data. Additionally, participant demographics were not collected in keeping with 
restrictions of a multi-center quality improvement project design; thus, we were unable to 
examine differences in barriers by patient age, disease duration, disease severity and 
treatment regimen complexity. Moreover, while our sample size was large, there were a 
small number of parent-patient dyads to assess for comparisons. Regardless, the multicenter 
design and unique coproduction model that was utilized for this study make it novel and 
innovative in the field of JIA adherence research.
By harnessing the collective coordination of a learning network, PR-COIN was able to lead 
the design and implementation effort of this Barriers Assessment Tool as part of a large, 
multi-center self-management initiative. Tracking introduction of the tool across sites 
allowed us to ensure feasibility in delivery of the tool across seven clinical settings. Both 
parent and provider feedback of the tool’s usability during both the design and delivery of 
the tool was encouraging that it can be successfully used to screen for and facilitate 
discussions surrounding non-adherence in any pediatric rheumatology clinic. Since its 
development, the BAT has been distributed for use among all 18 PR-COIN sites as part of a 
larger self-management optimization package. For access to this tool for research or clinical 
purposes, please contact the authors.
Future directions of this work will include design and testing of complementary adherence 
promotion tools to contribute to a larger systems-level adherence initiative. For example, 
multiple solutions to improve taste or forgetting medications have been used to improve 
adherence.47,48 Using such tools to increase dialogue between pediatric rheumatology 
providers and patients/families to identify and test various solutions based on individual 
needs (e.g., text-messages to remind people to take medications if they like technology or 
pairing medications with routines like brushing teeth) could be beneficial. Further, use of a 
standard set of adherence tools by clinical providers would systematize adherence solutions 
across patients. As with other chronic pediatric illnesses, formalizing adherence screening as 
a part of clinical care in JIA would likely continue to improve outcomes of this population. 
In JIA specifically, patient perceived adherence was related to better health related quality of 
life, particularly with gross motor and psychosocial functioning.44 Better adherence has also 
been linked to improvements in short-term outcomes in JIA including lower joint counts, 
improved physical functioning scores and parental perception of global improvement.49 
These findings continue to support the investigation and clinical emphasis in addressing 
adherence barriers in JIA. It is our intention to facilitate and ease discussions surrounding 
adherence behaviors and provide a usable system that will translate to more effective care in 
the JIA population.
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Figure 1. 
a and b Frequency of Parental Endorsed Barriers across Treatment Modalities.
This bar graph indicates the percentages of adherence barriers endorsed on the barriers 
assessment tool among parental respondents.
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Figure 2. 
a and b Frequency of Patient Endorsed Barriers across Treatment Modalities.
This bar graph indicates the percentages of adherence barriers endorsed on the barriers 
assessment tool among patient respondents.
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